AstraZeneca plc (NASDAQ:AZN) announced on Tuesday that it will acquire Fusion Pharmaceuticals Inc. for $21 per share or a total of approximately $2 billion, “a 97% premium to Fusion’s closing market price of $10.64 on 18th March 2024” in order to enhance its oncology portfolio.

“Together with Fusion, we have an opportunity to accelerate the development of FPI-2265 as a potential new treatment for prostate cancer, and to harness their innovative actinium-based platform to develop radioconjugates as foundational regimens,” AstraZeneca Executive Vice President, Oncology R&D Susan Galbraith said.

The transaction is expected to be completed in the second quarter of 2024, with Fusion becoming a wholly-owned subsidiary of AstraZeneca while maintaining its operations in the United States and Canada.

Join the discussion: Connect with other investors on your favorite stocks or explore the top-talked-about stocks on our Breakout Boards.

This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.